When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MKGAY - Merck KGaA out-licenses two gene-editing candidates to Vertex
Merck KGaA ADR
Merck KGaA (OTCPK:MKGAY) out-licenses exclusive rights to two DNA-dependent protein kinase (DNA-PK) inhibitors, M981 (formerly VX-984) and a preclinical candidate, to Vertex Pharmaceuticals (VRTX-0.8%) for gene-editing applications in six inherited diseases. The company says DNA-PK inhibitors can enhance the effectiveness of CRISPR/Cas9.
More news on: Merck KGaA ADR, Vertex Pharmaceuticals Incorporated, Healthcare stocks news,